* Clearside Biomedical Inc CLSD.OQ CLSD.O is expected
to show
a fall in quarterly revenue when it reports results on May 11.
* The Alpharetta Georgia-based company is expected to
report a
58.5% decrease in revenue to $144 thousand from $347 thousand a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Clearside
Biomedical Inc
is for a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Clearside
Biomedical Inc is $6, above its last closing price of $1.11.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.13 -0.13 -0.16 Missed -27
Sep. 30 2022 -0.05 -0.03 -0.13 Missed -282.4
Jun. 30 2022 -0.13 -0.13 -0.13 Met 1.5
Mar. 31 2022 -0.08 -0.08 -0.13 Missed -58.5
Dec. 0.12 0.16 0.31 Beat 95.8
31 2021
Sep. 30 2021 -0.10 -0.08 -0.08 Met 5.9
Jun. 30 2021 -0.13 -0.13 -0.11 Beat 14.3
Mar. 31 2021 -0.11 -0.10 -0.13 Missed -32.7
This summary was machine generated May 9 at 17:57 GMT. All
figures in US dollars unless otherwise stated